 SAN DIEGO, Nov. 9, 2021 PRNewswire -- Poseida Therapeutics, Inc. Nasdaq: PSTX, a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the upcoming presentation of preclinical data highlighting P-BCMA-ALLO1 for the treatment of relapsedrefractory multiple myeloma and P-MUC1C-ALLO1 for the treatment of multiple solid tumor indications at the Society for Immunotherapy of Cancer 2021 Annual Meeting SITC, being held in Washington, D.C., and virtually November 10-14, 2021. 